Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 24, 2026
Lockheed Martin (LMT) Delivers Strong Q2 Beat, Raises Guidance, and Sees +11.6% Stock Surge

Lockheed Martin (LMT) Delivers Strong Q2 Beat, Raises Guidance, and Sees +11.6% Stock Surge

Key Takeaways

  • Top and bottom line beat: Lockheed Martin reported Q2 2026 sales of $20.1 billion and earnings per share (EPS) of $7.94, exceeding consensus estimates of approximately $19.37 billion and $7.23, respectively.
  • Record $230 billion backlog: The company booked $65 billion in new orders during the quarter, achieving a book-to-bill ratio of 3.2 to 1, driven by major multi-year defense contracts including a $35 billion THAAD interceptor agreement.
  • Free cash flow rebound: Free cash flow swung from negative $150 million in Q2 2025 to positive $2.9 billion in Q2 2026, reflecting improved collections, lower tax payments, and operational efficiency.
  • Full-year guidance raised across the board: Management lifted its 2026 sales, EPS, segment operating profit, and free cash flow outlook, while reducing planned capital expenditures.
  • Stock surged in historic fashion: LMT shares jumped approximately 11% on July 23, marking the biggest single-day gain for the stock in nearly 25 years.

Earnings Context and Why It Matters

Lockheed Martin’s second quarter 2026 results carried outsized significance for investors because they landed against an easy but instructive year-ago comparison. In Q2 2025, the company booked approximately $1.6 billion in reach-forward losses tied to a classified Aeronautics program and two international helicopter contracts, compressing earnings to just $1.46 per share. This quarter’s clean operational performance offered a clearer read on the underlying earnings power of the world’s largest defense contractor. With global defense spending elevated and the Pentagon shifting toward multi-year procurement frameworks, Lockheed’s Q2 print served as a key checkpoint on whether rising budget commitments were actually translating into revenue, profit, and cash generation at scale.

Reported Results

Lockheed Martin reported second quarter 2026 sales of $20.1 billion, an 11% increase from $18.2 billion in the same period last year. Excluding prior-year unfavorable adjustments, organic sales growth was approximately 7%. The result handily exceeded the Wall Street consensus, which ranged between $19.33 billion and $19.52 billion depending on the data provider. I also checked this using Tickeron’s AI Screener to see how LMT compares with other names in the defense sector.

Diluted earnings per share came in at $7.94, well above analyst estimates of approximately $7.20 to $7.29. Net earnings reached $1.8 billion, compared to $342 million in Q2 2025. The year-over-year surge reflected the absence of the prior year’s program losses, along with broad-based volume growth and margin expansion. Segment operating profit was $2.2 billion, yielding a segment operating margin of 10.8%, a dramatic improvement from 3.1% a year ago.

Free cash flow was a standout metric, coming in at $2.9 billion versus negative $150 million in Q2 2025. Cash from operations totaled $3.2 billion, supported by favorable timing of customer receipts and lower tax payments. Capital expenditures for the quarter were $318 million. The company also returned $796 million to shareholders through dividends, sustaining a track record of 23 consecutive years of dividend increases.

All four business segments contributed to top-line growth. Missiles and Fire Control (MFC) led with a 19% sales increase and 24% profit growth, fueled by munitions production ramps and demand for systems such as GMLRS (Guided Multiple Launch Rocket System) and HIMARS (High Mobility Artillery Rocket System). Aeronautics, Rotary and Mission Systems (RMS), and Space each posted solid gains as well.

The company raised its full-year 2026 guidance: sales are now expected between $79.75 billion and $81.75 billion (up from $77.5 billion to $80 billion), implying approximately 8% year-over-year growth at the midpoint. EPS guidance moved to a range of $29.95 to $30.65, free cash flow guidance was lifted to $7.0 billion to $7.2 billion, and capital expenditure guidance was tightened to $2.0 billion to $2.4 billion, reflecting more efficient munitions capacity build-out plans.

Market Reaction and Investor Sentiment

Lockheed Martin shares surged 11.6% on July 23 to close at approximately $573.99, representing the stock’s largest single-day advance since September 2001. The rally pushed LMT through its 100-day moving average (100-DMA) for the first time in over three months, a technical signal that drew additional attention from momentum-oriented traders. The move stood in sharp contrast to the broader market, with the S&P 500 declining roughly 1.2% on the same day.

Investor enthusiasm was driven by the combination of an across-the-board beat, the record $230 billion backlog, and the raised full-year guidance. Analysts noted that while the easy year-ago comparison flattered the headline earnings growth rate, the underlying operational momentum—particularly the free cash flow recovery, munitions order strength, and improved capital efficiency—validated the company’s message of an accelerating growth trajectory. Retail sentiment on platforms such as Stocktwits flipped to “extremely bullish” within 24 hours of the release. Several sell-side analysts indicated the results supported a more durable, multi-year defense spending thesis rather than a one-quarter cyclical pop.

Using AI Tools to Refine Sector Analysis

In my view, one of the more efficient ways to stay on top of opportunities in defense and related industries is to incorporate data-driven screening tools into the research process. Tickeron’s AI Screener has become a regular part of how I review names like LMT. The platform lets users apply customizable filters for industry, market cap, technical indicators, price patterns, volatility, and AI-generated signals, which helps surface ideas or peer comparisons more quickly than manual methods. I find it particularly useful when trying to understand how a specific stock stacks up against broader sector trends or when looking for additional candidates that meet similar fundamental or technical criteria.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors have several important dynamics to track following this strong quarter.

First, execution on the record backlog will be critical. The $230 billion order book—boosted by the $35 billion THAAD (Terminal High Altitude Area Defense) contract, a $3 billion GMLRS award, and a $1.1 billion HIMARS deal—provides exceptional multi-year revenue visibility. However, translating these contracts into on-time deliveries and sustained margins will require continued production capacity expansion. Management’s decision to lower capital expenditure guidance while raising free cash flow targets suggests growing confidence in operational efficiency, but capacity constraints remain a risk worth monitoring.

Second, segment-level margin trajectories warrant attention. While Missiles and Fire Control is firing on all cylinders with mid-teens margins, Aeronautics faces modest margin headwinds as it ramps new F-35 contracts and works through earlier challenges on F-16 and C-130 programs. The Space segment, meanwhile, saw its full-year profit outlook trimmed due to reduced equity earnings from United Launch Alliance (ULA) tied to an ongoing technical investigation of a Vulcan launch anomaly earlier in the year.

Third, the macro defense spending backdrop remains supportive. The Department of Defense is seeking congressional approval for a $1.5 trillion budget, and geopolitical tensions continue to drive demand for Lockheed’s combat-proven systems from both the U.S. and allied nations. Management’s commentary on the earnings call emphasized that framework agreements with the Pentagon are designed to be long-term and enforceable, potentially insulating the multi-year growth trajectory from political turnover.

Finally, free cash flow generation and capital allocation will be closely watched. With full-year free cash flow now projected above $7 billion, investors will be looking for signs of accelerated share repurchases, further dividend increases, or strategic acquisitions—including the company’s recently announced agreement to acquire Ultra Maritime—that could deploy the strengthening balance sheet.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: LMT

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


LMT in +1.13% Uptrend, rising for three consecutive days on August 04, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where LMT advanced for three days, in of 348 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 23, 2026. You may want to consider a long position or call options on LMT as a result. In of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for LMT just turned positive on July 23, 2026. Looking at past instances where LMT's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

LMT moved above its 50-day moving average on July 23, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for LMT crossed bullishly above the 50-day moving average on July 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for LMT moved out of overbought territory on August 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LMT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

LMT broke above its upper Bollinger Band on July 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LMT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.337) is normal, around the industry mean (10.193). P/E Ratio (21.492) is within average values for comparable stocks, (64.003). Projected Growth (PEG Ratio) (1.206) is also within normal values, averaging (8.261). Dividend Yield (0.023) settles around the average of (0.016) among similar stocks. P/S Ratio (1.753) is also within normal values, averaging (35.983).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

Market Cap

The average market capitalization across the Aerospace & Defense Industry is 38.24B. The market cap for tickers in the group ranges from 4.49 to 1.43T. SPCX holds the highest valuation in this group at 1.43T. The lowest valued company is BDRPF at 4.49.

High and low price notable news

The average weekly price growth across all stocks in the Aerospace & Defense Industry was 8%. For the same Industry, the average monthly price growth was -2%, and the average quarterly price growth was 2%. VOYG experienced the highest price growth at 60%, while DFNS experienced the biggest fall at -46%.

Volume

The average weekly volume growth across all stocks in the Aerospace & Defense Industry was 51%. For the same stocks of the Industry, the average monthly volume growth was 42% and the average quarterly volume growth was 26%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 66
Price Growth Rating: 57
SMR Rating: 79
Profit Risk Rating: 72
Seasonality Score: -21 (-100 ... +100)
View a ticker or compare two or three
LMT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of components and systems for aerospace and defense use

Industry AerospaceDefense

Profile
Details
Industry
Aerospace And Defense
Address
6801 Rockledge Drive
Phone
+1 301 897-6000
Employees
122000
Web
https://www.lockheedmartin.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.